Drug firm Unichem Laboratories Thursday said a Europe court has upheld the decision to impose a fine of EUR 13.96 million (approx Rs 113.50 crore) on the company and its subsidiary by the European Commission (EC) in a litigation over blood pressure lowering drug Perindopril.
"General Court of the European Union has on December 12, 2018, rejected the appeals... and has confirmed the fine of EUR 13.96 million," Unichem Laboratories said in a regulatory filing.
The company said "it is disappointed and is currently reviewing the detailed judgment. It will take appropriate legal advice on further action, including the possibility of filing of an appeal before the Court of Justice of the European Union".
In 2014, Lupin and Unichem Laboratories were among six global drug makers on which the the European Commission had imposed a collective fine of EUR 427.7 million for striking deals to prevent entry of cheaper version of blood pressure drug Perindopril in the EU.
European Commission had imposed a fine of EUR 13.96 million on Unichem Laboratories and its subsidiary.
Niche Generics and Unichem then appealed the decision of the European Commission before the General Court of the European Union on September 22, 2014.
Niche is a wholly-owned subsidiary of Unichem Laboratories.
The court also upheld a fine of EUR 40 million (over Rs 325 crore) on Lupin.
Shares of Unichem Laboratories were trading 0.55 per cent lower at Rs 191.60 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
